medmix and NIPRO CORPORATION announce an exclusive promotion and distribution partnership for PiccoJect™ in the Japanese market

16 April 2024

medmix' Drug Delivery (“Haselmeier”) and NIPRO CORPORATION (“Nipro”) announce an exclusive promotion and distribution partnership for PiccoJect™ in the Japanese market.

Nipro and Haselmeier are pleased to announce a strategic cooperation to promote and distribute the PiccoJect autoinjector in the Japanese market. Haselmeier expands its distribution channels in Japan with Nipro as a strong and experienced partner.

Key highlights of the collaboration:

  • Partnership: Nipro will be the exclusive distributor of products based on the Haselmeier`s PiccoJect platform in Japan. This strong commitment underscores the confidence both companies have in PiccoJect’s potential.
  • Market Access: Pharma and biotechnology companies across Japan will now have access to PiccoJect, the next generation 2-step autoinjector of Haselmeier.
  • Quality: Nipro’s commitment to quality aligns with Haselmeier’s high standards. Together, they will ensure that PiccoJect maintains its strong performance and reliability.

“We are thrilled to partner with Haselmeier to introduce PiccoJect to the Japanese market. This collaboration reflects our commitment to advancing healthcare that positively impacts patients’ lives”, said Masanobu Iwasa, Director of the PharmaPacakaging Division, Nipro. Dominik Vonier, Managing Director of Haselmeier added: “Nipro’s extensive reach and reputation make them an ideal partner for PiccoJect. By combining Nipro’s expertise in pharmaceutical packaging and Haselmeier’s experience in drug delivery, this partnership contributes to advancing healthcare solutions. We look forward to a successful journey together.”

Key facts about PiccoJect:

  • Patient-centric design with an ergonomic shape, a large wrap-around drug window and a status indicator that provides clear binary feedback
  • Low part count of only eight parts
  • Committed to sustainability: Material with sustainable feedstocks and regional supply chain
  • A full-service platform including combination product development, design verification, final assembly, secondary packaging, labeling and serialization
  • Developed for a standard 1 mL long and 2.25 mL pre-filled glass or plastic syringes

Nipro will introduce PiccoJect to the Japanese market at CPHI Japan in Tokyo, April 17-19, 2024. PiccoJect will be available through Nipro from Q1/2025.

Figure 1: PiccoJect™ is a highly compact, customizable and fully featured two-step autoinjector designed for subcutaneous delivery of drug products.

About medmix

medmix is a global leader in high-precision delivery devices, with leading positions in healthcare, consumer and industrial end-markets. Our customers benefit from our dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2’700 employees are at service of our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX)

About Nipro PharmaPackaging Division

Nipro PharmaPackaging Division is specialized in developing and manufacturing pharmaceutical packaging products such as vials, syringes and rubber stoppers as well as administration support devices, and is committed to enhancing packaging solutions for new and existing medicines. We offer innovative, reliable, and sustainable packaging solutions that meet the specific requirements of our business partners. With a commitment to excellence, we strive to be the preferred packaging partner for our customers worldwide.


Media Relations, medmix:

Investor Relations, medmix:

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.